Description
Anti-CFB Antibody, Non-Fucosylated (BioBet-703ZP) is a humanized monoclonal IgG antibody against CFB. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Macular degeneration, age-related
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CFB antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CFB
Full Name
complement factor B
Background
This gene encodes complement factor B, a component of the alternative pathway of complement activation. Factor B circulates in the blood as a single chain polypeptide. Upon activation of the alternative pathway, it is cleaved by complement factor D yielding the noncatalytic chain Ba and the catalytic subunit Bb. The active subunit Bb is a serine protease which associates with C3b to form the alternative pathway C3 convertase. Bb is involved in the proliferation of preactivated B lymphocytes, while Ba inhibits their proliferation. This gene localizes to the major histocompatibility complex (MHC) class III region on chromosome 6. This cluster includes several genes involved in regulation of the immune reaction. Polymorphisms in this gene are associated with a reduced risk of age-related macular degeneration. The polyadenylation site of this gene is 421 bp from the 5 end of the gene for complement component 2.
Alternative Names
CFB; complement factor B; BF; FB; BFD; GBG; CFAB; CFBD; PBF2; AHUS4; FBI12; H2-Bf; ARMD14; C3 proactivator; C3/C5 convertase; C3 proaccelerator; properdin factor B; B-factor, properdin; glycine-rich beta glycoprotein; glycine-rich beta-glycoprotein
Gene ID
629
UniProt ID
P19022
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with CFB include Hemolytic Uremic Syndrome, Atypical 4 and Complement Factor B Deficiency.
Related Pathways
Its related pathways are Innate Immune System and Complement and coagulation cascades.
Function
As part of the alternative pathway of the complement system, factor B is broken down by D into two fragments: Ba and Bb. Then, serine protease Bb combines with complement factor 3b to generate C3 or C5 convertase. It also participates in the proliferation and differentiation of pre-activated b lymphocytes, the rapid proliferation of peripheral blood mononuclear cells, and stimulates the formation of lymphocytes and the lysis of red blood cells. Ba inhibits the proliferation of preactivated b lymphocytes.
Post-translational modifications
1.Glycosylation at Asn122, Asn142, Asn285, Lys291, and Asn378 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-703ZP
Description
The humanized anti-factor B antibody treating diseases or disorders in which activation of the alternative complement pathway plays a role.
Antibody Indication
Macular degeneration, age-related
Macular degeneration, age-related
